Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Association of soluble urokinase plasminogen activator receptor levels with fibrotic and vascular manifestations in systemic sclerosis

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Dancing with atrial fibrillation - How arrhythmia affects everyday life of family members: A qualitative study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Insulin resistance genetic risk score and burden of coronary artery disease in patients referred for coronary angiography

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Genetic markers of abdominal obesity and weight loss after gastric bypass surgery

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Maternal obesity and metabolic disorders associate with congenital heart defects in the offspring: A systematic review

    Research output: Contribution to journalReviewResearchpeer-review

  1. Early life body size, growth and risks of systemic lupus erythematosus - A large Danish observational cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Hydroxychloroquine in patients with rheumatic diseases during the COVID-19 pandemic: a letter to clinicians

    Research output: Contribution to journalLetterResearchpeer-review

  3. Accrual of Atherosclerotic Vascular Events in a Multicenter Inception Systemic Lupus Erythematosus Cohort

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

OBJECTIVE: We assessed the association of suPAR (soluble urokinase plasminogen activator receptor) plasma levels with fibrotic and vascular manifestations in patients with systemic sclerosis (SSc).

METHODS: suPAR plasma levels were measured in 121 consecutive patients with SSc and correlated to pulmonary and vascular features of SSc, including interstitial lung disease as characterized by percentage of predicted CO diffusing capacity (DLco) and forced vital capacity (FVC), pulmonary fibrosis by computed tomography, and pulmonary arterial hypertension, telangiectasias, and digital ulcers.

RESULTS: Overall, 121 SSc patients (84% females; mean age, 57 ± 12 [range: 22-79] years) were enrolled; 35% had diffuse cutaneous SSc. suPAR plasma levels ranged from 1.3-10.2 [median: 2.9 (p25-p75: 2.3-3.9)] ng/mL. Log(suPAR) levels correlated with DLco (r = -0.41, p <0.0001) and FVC (r = -0.26, p = 0.004), also when adjusted for age, sex, and pulmonary hypertension. A suPAR cut-off level of >2.5 ng/mL showed a sensitivity of 91% for identifying patients with either DLco <50% or FVC < 60% of the predicted values. Similarly, 19 (90%) had a suPAR >2.5 ng/mL among those diagnosed with pulmonary fibrosis vs. 59 (60%) among those who did not (p = 0.008). suPAR values were not associated with vascular manifestations.

CONCLUSION: suPAR levels strongly correlated with pulmonary involvement in SSc. Future studies should test if suPAR estimation can be used for surveillance of severe pulmonary involvement in SSc.

Original languageEnglish
Article numbere0247256
JournalPLoS One
Volume16
Issue number2
ISSN1932-6203
DOIs
Publication statusPublished - 22 Feb 2021

ID: 62392494